Journal article icon

Journal article

Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review

Abstract:

Ipilimumab (Yervoy; Medarex and Bristol-Myers Squibb) is a human MAB against cytotoxic T-lymphocyte antigen 4, which enhances co-stimulation of cytotoxic T-lymphocytes, resulting in their proliferation and an anti-tumour response. It is licensed for the treatment of unresectable or metastatic malignant melanoma, while multiple clinical trials using this medication in the treatment of other malignancies are ongoing. As a clinical response to ipilimumab results from immunostimulation, predictab...

Expand abstract

Actions


Access Document


Publisher copy:
10.1530/EJE-12-0167

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, OCDEM
Role:
Author
Journal:
European Journal of Endocrinology
Volume:
167
Issue:
1
Pages:
1-5
Publication date:
2012-07-05
DOI:
EISSN:
1479-683X
ISSN:
0804-4643
URN:
uuid:bc1120fb-47d7-406c-9604-41fc7450dfb8
Source identifiers:
341499
Local pid:
pubs:341499
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP